Ginseng-radix aconiti lateralis preparata decoction modified preparation and preparation method and application thereof

Abstract

The invention discloses a ginseng-radix aconiti lateralis praeparata decoction addition and reduction preparation, a preparation method and application thereof, and a traditional Chinese medicine composition, the ginseng-radix aconiti lateralis praeparata decoction addition and reduction preparation comprises ginseng, radix aconiti lateralis praeparata, salvia miltiorrhiza and platycodon grandiflorum according to a mass part ratio of 3: 2: (3-4): (2-3). The traditional Chinese medicine composition can effectively prevent and treat symptoms of silicosis fibrosis. The pharmacology of the traditional Chinese medicine composition is as follows: the ginseng is sweet, slightly bitter and slightly warm in taste, and has the effects of reinforcing vital energy, restoring pulse, relieving desertion, tonifying spleen, benefiting lung, promoting salivation, nourishing blood, soothing the nerves and improving intelligence; radix aconiti carmichaeli is pungent, sweet, hot and toxic, has the effects of recuperating yang and rescuing collapse, tonifying fire and supporting yang and eliminating cold to stop pain, and the radix aconiti carmichaeli and the radix aconiti carmichaeli are compatible with each other to reduce Salvia miltiorrhiza can eliminate oxygen free radicals, resist lipid peroxidation, inhibit collagen to repair unbalance and resist inflammation to relieve pulmonary fibrosis. Platycodon grandiflorum has anti-inflammatory, anti-virus, liver-protecting, immunity-regulating and anti-tumor effects.

Description

Technical Field

[0001] The invention belongs to the technical field of treating silicosis fibrosis, and specifically relates to a modified Shenfu decoction preparation and a preparation method and application thereof. Background Art

[0002] Silicosis is a disease caused by long-term inhalation of free silicon dioxide (SiO 2 ) is a disease caused by dust with diffuse fibrosis of lung tissue as the main manifestation. It is also one of the occupational diseases with the highest incidence rate and the main cause of labor loss of workers in dusty environments. Its main pathological changes are proliferation of pulmonary interstitial cells and excessive deposition of extracellular matrix leading to pulmonary fibrosis. Silicosis has a long history in my country. In the Shang and Zhou dynasties, there were people engaged in ceramics, mining and smelting. In the Song Dynasty, "Tan Yuan" recorded that "the quarrymen in Jiagu Mountain were injured by the stones, and many died of lung scorch." Later doctors had other theories on the cause of the disease, such as "metal and stone are hot" and "metal and stone are dry and toxic." For patients with silicosis fibrosis, they can take drugs such as acetylcysteine ​​tablets, pirfenidone tablets and nintedanib for treatment, but Western medicine treatment has the defects of high price, large side effects and treating symptoms but not the root cause. Therefore, it is urgent to develop traditional Chinese medicine compound preparations for the treatment of silicosis fibrosis. Summary of the invention

[0003] In view of the deficiencies in the prior art, an object of the present invention is to provide a Chinese medicine composition.

[0004] Another object of the present invention is to provide the use of the above-mentioned traditional Chinese medicine composition in the preparation of a medicine for treating pulmonary fibrosis.

[0005] A traditional Chinese medicine composition comprises ginseng, aconite root, salvia miltiorrhiza and platycodon grandiflorum, wherein the ratio of ginseng, aconite root, salvia miltiorrhiza and platycodon grandiflorum is 3:2:(3-4):(2-3) by weight.

[0006] A method for preparing a modified Shenfu decoction preparation comprises extracting the traditional Chinese medicine composition with water to obtain the modified Shenfu decoction preparation.

[0007] In the above technical scheme, the Chinese medicine composition is extracted with water to obtain the modified Shenfu Decoction preparation.

[0008] The use of the above-mentioned Chinese medicine composition in the preparation of a drug for treating pulmonary tissue fibrosis. The Chinese medicine composition of the present invention can effectively prevent and treat the symptoms of silicosis fibrosis. The pharmacology of the Chinese medicine composition of the present invention is as follows: ginseng tastes sweet, slightly bitter, slightly warm, has the effects of greatly replenishing vital energy, restoring pulse and consolidating collapse, replenishing spleen and lungs, promoting body fluid and nourishing blood, and calming the mind and improving intelligence; aconite is pungent, sweet, hot, and toxic, has the effects of restoring yang and rescuing adverse conditions, replenishing fire and yang, and dispersing cold and relieving pain, and the two are mutually complementary, reducing toxicity and increasing efficacy; salvia miltiorrhiza can relieve pulmonary fibrosis by scavenging oxygen free radicals, resisting lipid peroxidation, inhibiting collagen repair imbalance and anti-inflammatory; platycodon has anti-inflammatory, antiviral, liver-protecting, immune-regulating and anti-tumor effects. The drugs are matched together to play the effect of warming and nourishing the heart yang, warming and nourishing the kidney and lungs, promoting blood circulation and resolving phlegm, and have obvious effects on the treatment of silicosis fibrosis. BRIEF DESCRIPTION OF THE DRAWINGS

[0009] Figure 1 The morphology of lung tissue samples from Wistar rats in the model control group, silicosis model group, Shenfu Tang Jiajian preparation prevention group, and Shenfu Tang Jiajian preparation treatment group;

[0010] Figure 2 The statistical chart of the changes of lung coefficient indexes of Wistar rats in the model control group, silicosis model group, Shenfu Tang plus minus preparation prevention group and Shenfu Tang plus minus preparation treatment group;

[0011] Figure 3 HE staining images of lung tissues of Wistar rats in the model control group, silicosis model group, Shenfu Tang Jiajian preparation prevention group, and Shenfu Tang Jiajian preparation treatment group;

[0012] Figure 4 HE staining images of liver tissue and kidney tissue of Wistar rats in the model control group for 8 weeks, silicosis model group for 8 weeks, Shenfu Tang plus minus preparation prevention group and Shenfu Tang plus minus preparation treatment group;

[0013] Figure 5 The statistical chart of the number of white blood cells in bronchoalveolar lavage fluid of Wistar rats in the model control group, silicosis model group, Shenfu Tang plus minus preparation prevention group and Shenfu Tang plus minus preparation treatment group;

[0014] Figure 6 The Wright-Giemsa staining images of macrophages of Wistar rats in the model control group for 8 weeks, the silicosis model group, the prevention group of Shenfu Tang plus minus preparation, and the treatment group of Shenfu Tang plus minus preparation;

[0015] Figure 7 The immunohistochemical staining of α-SMA in lung tissue of Wistar rats in the model control group for 8 weeks, the silicosis model group for 8 weeks, the prevention group of Shenfu Tang plus minus preparation, and the treatment group of Shenfu Tang plus minus preparation;

[0016] Figure 8Western blot and α-SMA protein statistics of Wistar rats in the model control 8-week group, silicosis model 8-week group, Shenfu Tang Jiajian preparation prevention group and Shenfu Tang Jiajian preparation treatment group. DETAILED DESCRIPTION

[0017] The technical solution of the present invention is further described in detail below in conjunction with the accompanying drawings and embodiments.

[0018] The Wright-Giemsa stain solution was purchased from Zhuhai Beisu Biotechnology Co., Ltd. The Wright-Giemsa stain solution includes: Wright-Giemsa stain solution A and Wright-Giemsa stain solution B.

[0019] The loading buffer was purchased from Beijing Zhuangmeng International Biogene Technology Co., Ltd.;

[0020] In the following examples, a method for preparing a 4% paraformaldehyde fixative comprises: placing 2 g of paraformaldehyde powder in a 50 mL centrifuge tube, adding 50 mL of physiological saline, vortexing to completely dissolve the paraformaldehyde powder to obtain a 4% paraformaldehyde fixative, and storing the 4% paraformaldehyde fixative in a 4° C. refrigerator.

[0021] In the accompanying drawings, compared with the model control group with the same feeding time, ** indicates P < 0.01, *** indicates P < 0.01, and **** indicates P < 0.0001; compared with the silicosis model group for 8 weeks, ## indicates P < 0.01, ### indicates P < 0.001, and #### indicates P < 0.0001.

[0022] In the accompanying figure, n is the sample size, F value is the probability value, and when F>0.05, it means that there is no significant difference between the groups.

[0023] The concentration of sodium chloride in the physiological saline used in the following examples is 0.9 g / mL.

[0024] The modified Shenfu decoction preparation used in the following examples is sealed with a sealing film and stored in a refrigerator at 4° C. for use, and the storage time can be up to 2 weeks.

[0025] Example 1

[0026] A method for preparing a modified Shenfu decoction preparation comprises the following steps:

[0027] Weigh ginseng, aconite root, salvia miltiorrhiza and platycodon grandiflorum, put them into water and boil at 180°C (high heat), adjust to 80°C (low heat) after boiling, keep boiling slightly, continue decocting and concentrating until a modified Shenfu decoction is obtained, wherein the mass ratio of ginseng, aconite root, salvia miltiorrhiza and platycodon grandiflorum is 3:2:4:3, the mass fraction of ginseng, the volume fraction of water and the volume fraction of the modified Shenfu decoction are 15:900:200, the unit of mass fraction is g, and the unit of volume fraction is mL.

[0028] SiO 2 Suspension: weigh 2g SiO 2 The particles were ground thoroughly in a mortar and baked at 80°C for 4 hours. 2 The particles were placed in a 50 mL centrifuge tube, 40 mL of saline was weighed with a measuring cylinder and added to the centrifuge tube, and the mixture was thoroughly shaken to obtain SiO 2 Suspension (SiO 2 SiO in suspension 2 The concentration is 50 mg / mL), SiO 2 The suspension was sealed with sealing film and stored in a 4°C refrigerator for later use.

[0029] Specific pathogen-free (SPF) healthy adult Wistar rats were selected, and each Wistar rat weighed (200±20) g. All Wistar rats were raised in a pathogen-free environment at the Experimental Animal Center of North China Institute of Science and Technology. The experimental animals were divided into 12 groups according to the random number table method, with 6 Wistar rats in each group.

[0030] The 12 groups of experimental animals were divided into the following groups:

[0031] Model control group: Wistar rats were gavaged with 50 μL of normal saline daily and fed normally every day for X weeks, and then the Wistar rats were killed. The model control group was divided into model control 1 week group, model control 2 week group, model control 4 week group and model control 8 week group according to the feeding time (gavage time). Each group was gavaged continuously every day, and their numbers and X are shown in Table 1;

[0032] Table 1

[0033]

[0034]

[0035] Silicosis model group: Wistar rats were intubated in the oropharynx and trachea and infused with 1 mL SiO 2 The rats were fed with a suspension for dusting, and then fed normally every day for Y weeks. The Wistar rats were killed. The silicosis model group was divided into silicosis model 1 week group, silicosis model 2 week group, silicosis model 4 week group and silicosis model 8 week group according to the feeding time. Their numbers and Y are shown in Table 2.

[0036] Table 2

[0037] Silicosis model group serial number Y Week Silicosis model 1 week group Si1 1 week Silicosis model 2 weeks group Si2 2 weeks Silicosis model 4 weeks group Si4 4 weeks Silicosis model 8 weeks group Si8 8 weeks

[0038] The prevention group of Shenfu Decoction plus minus preparation: Wistar rats were intragastrically administered with the Shenfu Decoction plus minus preparation prepared in Example 1. The mass of the Shenfu Decoction plus minus preparation prepared in Example 1 per kg of body weight of the Wistar rats was 6.25 g. After intragastrically administering the Shenfu Decoction plus minus preparation prepared in Example 1 for 48 hours, the Wistar rats were infused with 1 mL of SiO 2 The suspension was used for dust exposure, and the rats were fed normally every day after dust exposure. After 8 weeks of feeding, the Wistar rats were killed. Among them, the prevention group of Shenfu Decoction was numbered as Pre;

[0039] Treatment group: Wistar rats were intubated in the oropharynx and trachea and infused with 1 mL SiO 2 The suspension was used for dusting. After 48 hours of dusting, the rats were gavaged with the Shenfu Decoction prepared in Example 1 every day. The amount of Shenfu Decoction prepared in Example 1 per 1 kg of body weight of Wistar rats was W, and the body weight of the Wistar rats was weighed every 7 days. The dosage of the Shenfu Decoction prepared in Example 1 was adjusted according to the change in their body weight. After continuous feeding for 8 weeks, the Wistar rats were killed. Among them, the Shenfu Decoction treatment group was divided into a Shenfu Decoction high-dose treatment group, a Shenfu Decoction medium-dose treatment group and a Shenfu Decoction low-dose treatment group according to the dose of the Shenfu Decoction. Their numbers and W are shown in Table 3.

[0040] Table 3

[0041]

[0042]

[0043] Animal Experimentation:

[0044] (1) Experimental solvent:

[0045] 3% sodium pentobarbital solution: Weigh 3 g of sodium pentobarbital powder using a balance, pour the sodium pentobarbital powder into a 200 mL volumetric flask, add 100 mL of normal saline, dissolve and mix to obtain a 3 g / mL sodium pentobarbital solution, and store in a refrigerator at 4°C for later use.

[0046] (2) Experimental procedures:

[0047] The Wistar rats in the above experimental animal groups were killed by overdose anesthesia with 3% sodium pentobarbital solution, and the killed Wistar rats were fixed on the operating table, and the fur from the neck to the xiphoid process was wiped with a cotton ball soaked in physiological saline. A longitudinal incision was made from the neck to the sternal manubrium, and the layers were peeled away until the trachea and lungs were exposed. A T-shaped incision was made in the trachea, and a cannula was intubated and fixed with a thin thread. 5 mL of physiological saline was drawn with a 5 mL syringe and the lungs were lavaged through the cannula. Lavage was performed three times until the alveoli turned white. The alveolar lavage fluid (15 mL) was collected three times and placed in a 15 mL centrifuge tube and mixed, and filtered with a double-layer sterile gauze to obtain bronchoalveolar lavage fluid (BALF). The BALF was placed in a centrifuge tube and stored in an ice box.

[0048] The lungs, livers and kidneys of Wistar rats were completely separated, the surrounding connective tissues were carefully removed, the thin wires were cut and the cannulas were recovered, the lungs were flushed with saline, the lungs were photographed, the color, gloss, texture, elasticity, lung congestion and swelling of both lungs were observed with the naked eye, and the gross images of the animal samples were preserved. The right lower lobe of the lung was taken for the observation of lung tissue pathology, and the remaining lobes of the lung were placed in different centrifuge tubes and stored in a -80°C refrigerator for Western blot analysis.

[0049] Figure 1 The lung tissue samples of Wistar rats in the model control group, silicosis model group, Shenfu Tang Jiajian preparation prevention group and Shenfu Tang Jiajian preparation treatment group were collected by Figure 1 It can be seen that the surface of the lung tissue of the model control group was smooth, and no obvious granular nodules were found; there were granular nodules on the surface of the lung tissue of the silicosis model 1-week group, silicosis model 2-week group, silicosis model 4-week group and silicosis model 8-week group, and the granular nodules became more obvious with the extension of the feeding time; granular nodules were visible on the surface of the lung tissue of the Shenfu Tang Jiajian preparation prevention group, but the range of granular nodules was smaller than that of the silicosis model 8-week group; compared with the silicosis model 8-week group, although there were granular nodules on the surface of the lung tissue of the Shenfu Tang Jiajian preparation treatment group, the range of granular nodules was smaller than that of the silicosis model 8-week group. Compared with the Shenfu Tang Jiajian preparation high-dose treatment group, the Shenfu Tang Jiajian preparation medium-dose treatment group and the Shenfu Tang Jiajian preparation low-dose treatment group, the lungs of the Shenfu Tang Jiajian preparation high-dose treatment group were pink, soft in texture, and the granular nodules were significantly smaller than those of the Shenfu Tang Jiajian preparation low-dose treatment group and the Shenfu Tang Jiajian preparation medium-dose treatment group. These experimental results indicate that the fibrosis symptoms of rats were alleviated after administration of the modified Shenfu Decoction, and Shenfu Decoction has the potential to prevent and treat silicotic fibrosis.

[0050] The lungs were rinsed with physiological saline and then dried with filter paper. The wet weight of the lungs was measured using an electronic balance and the lung coefficient was calculated: lung coefficient = (wet weight of lungs / body weight of Wistar rats) × 100%. Figure 2This is a statistical chart showing the changes in lung coefficient indicators of Wistar rats in the model control group, silicosis model group, Shenfu Decoction plus or minus preparation prevention group and Shenfu Decoction plus or minus preparation treatment group. Compared with the model control group, the lung coefficient of Wistar rats in the silicosis model group was significantly increased. After treatment with Shenfu Decoction plus or minus preparation, the lung coefficient of Wistar rats in the Shenfu Decoction plus or minus preparation treatment group was reduced, and was dose-dependent.

[0051] To further investigate the pathological morphology of the lung tissue of Wistar rats in each experimental animal group, the right lower lobe of the lung was immersed in a pre-prepared 4% paraformaldehyde fixative, fixed in a 4°C refrigerator for 48 hours, embedded in paraffin, and sliced ​​(the slice thickness was 4 μm). The lung tissue sections of Wistar rats were stained with hematoxylin-eosin (HE) for observation. Figure 3 As shown, Figure 3 HE staining of lung tissues of Wistar rats in the model control group, silicosis model group, Shenfu Tang Jiajian preparation prevention group, and Shenfu Tang Jiajian preparation treatment group. Figure 3 It can be seen that the alveolar tissue structure of Wistar rats in the 8-week model control group was normal, and no obvious inflammatory cell infiltration was observed. The silicotic silicotic nodules of Wistar rats in the 8-week silicosis model group were obvious, the alveolar tissue septa were thickened, and inflammatory cell infiltration was observed. Silicotic silicotic nodules were present in the prevention group of Shenfu Decoction and the treatment group of Shenfu Decoction, and the alveolar septa were thickened and inflammatory cells were infiltrated. However, the fibrosis area was smaller than that in the 8-week silicosis model group. Compared with the prevention group of Shenfu Decoction and the low-dose treatment group of Shenfu Decoction, the lung tissue of Wistar rats in the medium-dose treatment group of Shenfu Decoction and the high-dose treatment group of Shenfu Decoction showed reduced inflammatory cell infiltration and reduced silicotic nodule area.

[0052] The liver and kidney were immersed in a pre-prepared 4% paraformaldehyde fixative, fixed in a 4°C refrigerator for 48 hours, embedded in paraffin, and sliced ​​(slice thickness was 4 μm). The liver and kidney tissue slices of Wistar rats were stained with HE for observation. Figure 4 HE staining images of liver tissue and kidney tissue of Wistar rats in the model control 8-week group, silicosis model 8-week group, Shenfu Tang Jiajian preparation prevention group and Shenfu Tang Jiajian preparation treatment group. Figure 4 The first and third rows of the HE results of liver tissue are Figure 4 It can be seen that the liver cells of Wistar rats in the 8-week model control group, the prevention group of Shenfu Decoction plus or minus preparation, and the treatment group of Shenfu Decoction plus or minus preparation were neatly arranged and radiated in cords, without necrosis and degeneration, the liver lobule structure was not destroyed and was intact and clear, and no obvious abnormal proliferation of connective tissue was found in the portal area. Figure 4The second and fourth rows are the HE results of renal tissue. The results show that the glomerular structure of Wistar rats in the model control 8-week group, the prevention group of Shenfu Decoction plus or minus preparation, and the treatment group of Shenfu Decoction plus or minus preparation were clear, the renal collecting ducts were arranged tightly and regularly, the renal tubular epithelial cells were arranged regularly and the basement membrane was intact, and no inflammatory cell infiltration was observed. The above results indicate that Shenfu Decoction plus or minus preparation is non-toxic to Wistar rats.

[0053] Take 1 mL of bronchoalveolar lavage fluid (BALF) and dilute it 20 times with normal saline. Take 10 μL of the diluted BALF and add it to the bovine Bowman cell counting plate. Under an optical microscope, count the total number of white blood cells in the four large squares at the four corners of the bovine Bowman cell counting plate. The cell counting formula is: number of cells / mL = (total number of white blood cells / 4) × dilution factor × 10 4 mL. Figure 5 Figure 1 is a statistical chart of the number of white blood cells in bronchoalveolar lavage fluid of Wistar rats in the model control group, silicosis model group, Shenfu Tang Jiajian preparation prevention group, and Shenfu Tang Jiajian preparation treatment group. Figure 5 It can be seen that compared with the model control group, the total white blood cell count in the bronchoalveolar lavage fluid of Wistar rats in the silica-induced silicosis model group was significantly increased, and different doses of Shenfu Decoction plus minus preparation treatment groups could significantly reduce the total white blood cell count in the BALF of Wistar rats in the silica-induced silicosis model group. Among the Shenfu Decoction plus minus preparation treatment groups, the Shenfu Decoction plus minus preparation medium dose treatment group and the Shenfu Decoction plus minus preparation high dose treatment group could better reduce the total white blood cell count in the BALF.

[0054] The remaining 14 mL of BALF was further placed in a 4°C centrifuge and centrifuged at 12000 g for 10 min to obtain a cell pellet. The cell pellet was resuspended with 0.5 mL of precooled (4°C) physiological saline and fully blown to obtain a cell suspension. 5 μL of the cell suspension was aspirated and placed on a clean glass slide for cell smear. After smearing, a fixed area was circled with a crayon. After it was slightly dried, it was fixed with 4% paraformaldehyde fixative for 20 min, and then Wright-Giemsa staining was performed: according to the Wright-Giemsa method According to the instructions of the Wright-Giemsa stain reagent, add 0.5mL of Wright-Giemsa stain A onto the smear and 20s later, add 1mL of Wright-Giemsa stain B onto the Wright-Giemsa stain A. Use an ear bulb to blow gently to mix the Wright-Giemsa stain A and Wright-Giemsa stain B. After staining for 1 minute, rinse with PBS buffer (PH=7), then rinse with tap water, and place in a fume hood to air dry. Observe the number of macrophages on the air-dried slide under an optical microscope.

[0055] Figure 6Figure 2 is the Wright-Giemsa staining of macrophages in the model control group for 8 weeks, the silicosis model group, the prevention group of Shenfu Decoction plus minus preparation, and the treatment group of Shenfu Decoction plus minus preparation. Figure 6 It can be seen that compared with the model control 8-week group, the macrophages of Wistar rats in the silicosis model group increased significantly with the extension of feeding time. Compared with the silicosis model group, the number of macrophages of Wistar rats in the prevention group of Shenfu Decoction plus or minus preparation decreased, and the number of macrophages of Wistar rats in the treatment groups of different doses of Shenfu Decoction plus or minus preparation decreased significantly.

[0056] Figure 7 Expression of α-SMA in lung tissue of Wistar rats in the model control group for 8 weeks, silicosis model group for 8 weeks, Shenfu Tang plus minus preparation prevention group, and Shenfu Tang plus minus preparation treatment group. Figure 7 It can be seen that α-smooth muscle actin (α-SMA) was positively expressed in large quantities in the silicotic nodules and interstitial fibrosis areas of the lung tissue of Wistar rats in the 8-week silicosis model group, and the expression intensity and area were particularly obvious, while the positive expression range and intensity of the model control 8-week group, the Shenfu Decoction prevention group and the Shenfu Decoction treatment group were significantly weaker than those in the 8-week silicosis model group.

[0057] The lung tissue stored in the centrifuge tube was cut into 80 mg small pieces, 600uL tissue cell lysis solution and 6uL protease inhibitor were added, homogenized, and then lysed on ice for 40 minutes to obtain a lysate. The lysate was centrifuged at 12,000×g for 10 minutes at 4°C, and the supernatant (i.e., α-SMA protein) was taken. The α-SMA protein was diluted with ultrapure water to obtain a diluent. The concentration of the diluent was 10ug / uL. The diluent was mixed with the loading buffer. The volume ratio of the diluent to the loading buffer was 4:1. It was heated at 100°C for 10 minutes, cooled, and subjected to Western blot analysis. β-actin was used as an internal reference. The results are as follows: Figure 8 As shown, Figure 8 Western blot and α-SMA protein statistics of Wistar rats in the model control 8-week group, silicosis model 8-week group, Shenfu Tang Jiajian preparation prevention group and Shenfu Tang Jiajian preparation treatment group. Figure 8It can be seen that in Western blot, the expression of α-SMA protein in the lung tissue of Wistar rats in the 8-week silicosis model group was significantly higher than that in the 8-week model control group. Compared with the 8-week silicosis model group, the expression of α-SMA protein in the lung tissue of Wistar rats in the prevention group and the treatment group of Shenfu Tang Jiajian preparation was significantly decreased, among which, the expression of α-SMA protein in the high-dose treatment group of Shenfu Tang Jiajian preparation was close to that in the 8-week model control group, and α-SMA protein is a marker protein of myofibroblasts, which represents the degree of pulmonary fibrosis to some extent. The decrease of α-SMA protein indicates that the degree of fibrosis is improved. Therefore, the high-dose treatment group of Shenfu Tang Jiajian preparation can significantly alleviate silicosis fibrosis in rats, indicating that Shenfu Tang Jiajian preparation can effectively treat pulmonary fibrosis.

[0058] The present invention is described above by way of example. It should be noted that, without departing from the core of the present invention, any simple deformation, modification or other equivalent replacement that can be made by those skilled in the art without inventive effort falls within the protection scope of the present invention.

Claims

1. A Chinese medicine composition, characterized in that: include: The ratio of ginseng, aconite root, salvia miltiorrhiza and platycodon grandiflorum is 3:2:(3~4):(2~3) in terms of weight.

2. A method for preparing a modified Shenfu decoction, characterized in that: The Chinese medicine composition according to claim 1 is subjected to water extraction to obtain the modified Shenfu Decoction.

3. The preparation method according to claim 2, characterized in that: The Chinese medicine composition is extracted with water to obtain the modified Shenfu decoction preparation.

4. Use of the Chinese medicine composition as claimed in claim 1 in preparing a medicine for treating pulmonary fibrosis.

Images